Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells

作者
Basil Allen,Daniel Bottomly,Anthony Wang,Thomas Köhnke,Lindsey Savoy,Peter Ryabini,Reid Chen,Kara J. Johnson,Stephen E. Kurtz,Anupriya Agarwal,Michelle Craig Barton,Brian J. Druker,Ravindra Majeti,Jeffrey W Tyner,Shannon K. McWeeney,Haijiao Zhang
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 2937-2937
标识
DOI:10.1182/blood-2023-178096
摘要

Introduction:Ventoclax-based combinations have emerged as a new standard of care for patients with acute myeloid leukemia (AML) who are not suitable for intense chemotherapy. Not all patients respond to these treatments, and those who do may relapse. MDM2 inhibitors are promising therapeutics for treating TP53 wild-type tumors, including most de novo AML cases, with numerous compounds currently in pre-clinical and clinical evaluation. However, clinical trials of MDM2 inhibitors have shown modest and variable clinical activity. Functional genomic data showed that monocytic leukemia (FAB M4/M5) is resistant to venetoclax-based therapies and MDM2 inhibitors. Notably, venetoclax and an MDM2 inhibitor, idasanutlin, demonstrated a strong positive correlation in the Beat AML cohort. We hypothesize that upregulation of certain myeloid transcription factors in monocytic leukemia may confer intrinsic resistance to BCL2 and MDM2 inhibitors, while certain environmental cues upregulated in these cells may confer extrinsic drug resistance. Additionally, there may be crosstalk between these intrinsic and extrinsic mechanisms. Methods: We performed differential expression gene (DEG) analysis of transcription factors (TFs) between M4/M5 and M0/M1 samples in the Beat AML and TCGA AML cohort. We overexpressed seven myeloid TFs (SPI1, CEBPB, CEBPD, JUNB, IRF8, KLF4, and MAFB) that are upregulated in M4/M5 and performed competitive drug assays. We treated M4/M5 and M0/M1 samples with venetoclax and idasanutlin, in the presence of a panel of myeloid cytokines and measured cell viabilities. A Luminex assay on monocyte supernatants from M4/M5 and M0/M1 AML samples were conducted to identify dysregulated cytokines. Furthermore, RNAseq DEG and immunoblot analysis were performed on CEBPB-overexpressing cell lines and IL-1-treated AML samples to elucidate the underlying mechanisms. Results: CEBPB overexpression conferred drug resistance to a broad range of BH3 mimetics, venetoclax combinations, and MDM2 inhibitors. RNA-seq and immunoblot analyses demonstrated that CEBPB overexpression downregulated CASP3, CASP6, BCL2, and TP53 pathway targets (CDKN1A, PMAIP1, BBC3, BMF, TP53), while upregulated MCL1, BCL2A1, and the NF-κB/IL-1/TNF pathway at transcription and/or translation levels. Phenotyping analysis showed that CEBPB overexpression drives myelo/monocytic differentiation. In accordance, CEBPB expression in primary AML correlates with drug responses of idasanutlin, venetoclax, and many venetoclax combinations. Additionally, primary monocytic leukemia expresses significantly higher levels of IL-1/TNF family genes, BCL2A1, and reduced CASP3, CASP6, and BCL2. Abnormal monocytes, but not granulocytes, T cells, or blasts from M4/M5 leukemia, extrinsically protect leukemia blasts from venetoclax and MDM2 inhibition by secreting elevated IL-1 and TNFα. IL-1β/TNFα treatment drove myelo/monocytic differentiation and up-regulated inflammatory cytokines, including an autoregulatory loop, as well as a number of cytokine receptors, such as IL1R1, TNFRSF1R, TNFRSF2R, and CSF2RB. Remarkably, IL-1α/IL-1β and TNFα uniquely upregulated CEBPB expression in M4/M5 cells and protected them from apoptosis induced by venetoclax and MDM2 inhibitors. Conversely, TNFα treatment induced augmented extrinsic apoptosis in M0/M1 leukemia cells. Interestingly, treatment with venetoclax and idasanutlin led to a feedback upregulation of CEBPB, IL-1β, and/or TNFα, along with their respective receptors, and promoted myelomonocytic differentiation. IL-1/TNFα antagonists or an IRAK inhibitor alone did not kill leukemia cells, but they showed synergistic cytotoxicity when combined with venetoclax and idasanutlin. Conclusions: In summary, we have described a positive feedback loop between CEBPB, IL-1/TNFα, and monocytic differentiation in monocytic leukemia that contributes to intrinsic and extrinsic drug resistance against BCL2 and MDM2 inhibitors. This crosstalk and the consequent drug resistance are further reinforced by venetoclax/MDM2 inhibition treatment. Combining venetoclax or idasanutlin with IL-1/TNFα antagonists or an IRAK inhibitor can abrogate the feedback loop and induce synergistic cytotoxic effects, offering promising therapeutic strategies to enhance the treatment efficacy of venetoclax and MDM2 inhibitors for monocytic leukemia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NiuNiu4完成签到,获得积分10
刚刚
1秒前
1秒前
ranrika完成签到,获得积分10
1秒前
无花果的应助被ddd采纳,获得10
2秒前
2秒前
王悦完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
余谏己完成签到 ,获得积分10
4秒前
深情安青的应助被科研通管家采纳,获得10
4秒前
天天向上的应助被科研通管家采纳,获得30
4秒前
4秒前
Jasper的应助被科研通管家采纳,获得30
4秒前
上官若男的应助被科研通管家采纳,获得10
4秒前
赘婿的应助被科研通管家采纳,获得10
4秒前
Akim的应助被pinguin采纳,获得10
4秒前
JamesPei的应助被科研通管家采纳,获得10
4秒前
DW的应助被科研通管家采纳,获得10
4秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
5秒前
leecopper001发布了新的文献求助10
5秒前
搜集达人的应助被科研通管家采纳,获得10
5秒前
小二郎的应助被科研通管家采纳,获得10
5秒前
ding的应助被科研通管家采纳,获得10
5秒前
why发布了新的文献求助10
5秒前
orixero的应助被科研通管家采纳,获得10
5秒前
上官若男的应助被科研通管家采纳,获得10
5秒前
5秒前
华仔的应助被科研通管家采纳,获得30
5秒前
李68发布了新的文献求助10
5秒前
在望的应助被科研通管家采纳,获得10
6秒前
fantasy的应助被科研通管家采纳,获得10
6秒前
molihuakai的应助被科研通管家采纳,获得10
6秒前
6秒前
风吹麦浪发布了新的文献求助10
6秒前
大个的应助被科研通管家采纳,获得10
6秒前
6秒前
Orange的应助被科研通管家采纳,获得10
6秒前
风吹麦浪发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611